Elisabeth Eppard
Overview
Explore the profile of Elisabeth Eppard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
1024
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aghahosseini F, Salehi Y, Farzanefar S, Bakhshi Kashi M, Eppard E, Ahmadzadehfar H, et al.
Curr Radiopharm
. 2024 Jul;
18(1):23-36.
PMID: 39039681
Dementia (the most common cause of Alzheimer's disease) is defined as a chronic or progressive syndrome with disturbance of multiple cortical functions, the most important of them including memory, learning...
2.
Vahidfar N, Ahmadzadehfar H, Farzanefar S, Abbasi M, Salehi Y, Saboktakin F, et al.
Curr Radiopharm
. 2024 Mar;
17(4):320-329.
PMID: 38504563
Immunotherapy has emerged as a very considerable and potent therapeutic method in which immune inhibitors have gained a lot of attention in the curative field of various cancers. Under certain...
3.
Evangelista L, Guglielmo P, Pietrzak A, Lazar A, Urso L, Aghaee A, et al.
Semin Nucl Med
. 2024 Jan;
54(2):302-310.
PMID: 38218670
This work discusses the role of Nuclear Medicine for women's health, the role of women in the development of this emerging field and the various issues which arise from both....
4.
Haeger A, Soza-Ried C, Kramer V, Hurtado de Mendoza A, Eppard E, Emmanuel N, et al.
Cancers (Basel)
. 2023 Jan;
15(2).
PMID: 36672388
PET imaging of neuroendocrine tumours (NET) is well established for staging and therapy follow-up. The short half-life, increasing costs, and regulatory issues significantly limit the availability of approved imaging agents,...
5.
Siminzar P, Tohidkia M, Eppard E, Vahidfar N, Tarighatnia A, Aghanejad A
Mol Imaging Biol
. 2022 Dec;
25(3):464-482.
PMID: 36517729
The tumor microenvironment (TME) play critical roles in tumor survival, progression, and metastasis and can be considered potential targets for molecular imaging of cancer. The targeting agents for imaging of...
6.
Vahidfar N, Farzanefar S, Ahmadzadehfar H, Molloy E, Eppard E
Cancers (Basel)
. 2022 Apr;
14(7).
PMID: 35406552
Nuclear medicine is defined as the diagnosis and the treatment of disease using radiolabeled compounds known as radiopharmaceuticals. Single-photon emission computed tomography/computed tomography (SPECT/CT) and positron emission tomography/computer tomography (PET/CT)...
7.
Vahidfar N, Eppard E, Farzanehfar S, Yordanova A, Fallahpoor M, Ahmadzadehfar H
PET Clin
. 2021 May;
16(3):327-340.
PMID: 34053577
Radiometal-based theranostics or theragnostics, first used in the early 2000s, is the combined application of diagnostic and therapeutic agents that target the same molecule, and represents a considerable advancement in...
8.
Vahidfar N, Aghanejad A, Ahmadzadehfar H, Farzanehfar S, Eppard E
Int J Mol Sci
. 2021 Apr;
22(9).
PMID: 33925632
The implication of 'theranostic' refers to targeting an identical receptor for diagnostic and therapeutic purposes, by the same radioligand, simultaneously or separately. In regard to extensive efforts, many considerable theranostic...
9.
Fernandez R, Eppard E, Lehnert W, Jimenez-Franco L, Soza-Ried C, Ceballos M, et al.
J Nucl Med
. 2021 Jan;
62(8):1126-1132.
PMID: 33419945
Palliative treatment of bone metastasis using radiolabeled bisphosphonates is a well-known concept proven to be safe and effective. A new therapeutic radiopharmaceutical for bone metastasis is Lu-DOTA-zoledronic acid (Lu-DOTA-ZOL). In...
10.
Kramer V, Fernandez R, Lehnert W, Jimenez-Franco L, Soza-Ried C, Eppard E, et al.
Eur J Nucl Med Mol Imaging
. 2020 Sep;
48(3):893-903.
PMID: 32949253
Introduction: PSMA-targeted radionuclide therapy with lutetium-177 has emerged as an effective treatment option for metastatic, castration-resistant prostate cancer (mCRPC). Recently, the concept of modifying PSMA radioligands with an albumin-binding entity...